APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma

This trial tests an engineered immune cell therapy (called APRIL CAR-T cells) for people with relapsed or treatment-resistant multiple myeloma — a cancer of the blood — that is positive for certain markers (BCMA and/or TACI) on the cancer cells. **You may be eligible if...** - You are 18–75 years old - You have multiple myeloma that has relapsed, including after prior BCMA-targeted CAR-T therapy or stem cell transplant - Your cancer tests positive for BCMA and/or TACI - Your heart, liver, and kidney function are within acceptable ranges - Your ECOG performance status is 0–2 **You may NOT be eligible if...** - You have a history of brain injury, epilepsy, stroke, or significant heart rhythm problems - You are pregnant or breastfeeding - You have a severe active infection, active hepatitis B or C, or HIV - You have received systemic steroids within the past 2 weeks - You have previously received any CAR-T or genetically modified T-cell therapy Talk to your doctor to see if this trial is right for you.